Bromday Battle Broadens: Ocular Drug Infection Risks, Fill Size Limits Will Get FDA Cmte. Scrutiny

The Dermatologic and Ophthalmic Drugs Advisory Committee will meet Feb. 27 to discuss issues at the heart of Bromday marketer ISTA Pharmaceuticals’ dispute with the Center for Drug Evaluation and Research over post-operative use of a single-bottle ophthalmic agent in both eyes.